Show simple item record

dc.contributor.authorMurphy, Catriona
dc.contributor.authorBennett, Kathleen
dc.contributor.authorFahey, Tom
dc.contributor.authorShelley, Emer
dc.contributor.authorGraham, Ian
dc.contributor.authorKenny, Rose Anne
dc.date.accessioned2015-08-18T12:08:40Zen
dc.date.available2015-08-18T12:08:40Zen
dc.date.issued2015-07en
dc.identifier.citationStatin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA). 2015, 5 (7):e008017 BMJ Openen
dc.identifier.issn2044-6055en
dc.identifier.pmid26169806en
dc.identifier.doi10.1136/bmjopen-2015-008017en
dc.identifier.urihttp://hdl.handle.net/10147/575051en
dc.descriptionStatin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA)en
dc.description.abstractThis study aims to examine the extent to which statins are used by adults at high risk of cardiovascular disease (CVD) compared to European clinical guidelines. The high-risk groups examined are those with (1) known CVD, (2) known diabetes and (3) a high or very high risk (≥5%) of CVD mortality based on Systematic COronary Risk Evaluation (SCORE).
dc.description.abstractThis study is cross-sectional in design using data from the first wave (2009-2011) of The Irish Longitudinal Study on Ageing (TILDA).
dc.description.abstractThe sample (n=3372) is representative of community living adults aged 50-64 years in Ireland.
dc.description.abstractStatins were used by 68.6% (95% CI 61.5% to 75.8%) of those with known CVD, 57.4% (95% CI 49.1% to 65.7%) of those with known diabetes and by 19.7% (95% CI 13.0% to 26.3%) of adults with a SCORE risk ≥5%. Over a third (38.5%, 95% CI 31.0% to 46.0%) of those with known CVD, 46.8% (95% CI 38.4% to 55.1%) of those with known diabetes and 85.2% (95% CI 79.3% to 91.1%) of those with a SCORE risk ≥5% were at or above the low-density lipoprotein cholesterol (LDL-C) target of 2.5 mmol/L specified in the 2007 European guidelines.
dc.description.abstractDespite strong evidence and clinical guidelines recommending the use of statins for secondary prevention, a gap exists between guidelines and practice in this cohort. It is also of concern that a low proportion of adults with a SCORE risk ≥5% were taking statins. A policy response that strengthens secondary prevention, and improves risk assessment and shared decision-making in the primary prevention of CVD is required.
dc.language.isoenen
dc.publisherBMJ Openen
dc.rightsArchived with thanks to BMJ openen
dc.subjectCARDIOVASCULAR DISEASEen
dc.subjectOLDER PEOPLEen
dc.titleStatin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA).en
dc.typeArticleen
dc.identifier.journalBMJ openen
refterms.dateFOA2018-08-27T05:30:53Z
html.description.abstractThis study aims to examine the extent to which statins are used by adults at high risk of cardiovascular disease (CVD) compared to European clinical guidelines. The high-risk groups examined are those with (1) known CVD, (2) known diabetes and (3) a high or very high risk (≥5%) of CVD mortality based on Systematic COronary Risk Evaluation (SCORE).
html.description.abstractThis study is cross-sectional in design using data from the first wave (2009-2011) of The Irish Longitudinal Study on Ageing (TILDA).
html.description.abstractThe sample (n=3372) is representative of community living adults aged 50-64 years in Ireland.
html.description.abstractStatins were used by 68.6% (95% CI 61.5% to 75.8%) of those with known CVD, 57.4% (95% CI 49.1% to 65.7%) of those with known diabetes and by 19.7% (95% CI 13.0% to 26.3%) of adults with a SCORE risk ≥5%. Over a third (38.5%, 95% CI 31.0% to 46.0%) of those with known CVD, 46.8% (95% CI 38.4% to 55.1%) of those with known diabetes and 85.2% (95% CI 79.3% to 91.1%) of those with a SCORE risk ≥5% were at or above the low-density lipoprotein cholesterol (LDL-C) target of 2.5 mmol/L specified in the 2007 European guidelines.
html.description.abstractDespite strong evidence and clinical guidelines recommending the use of statins for secondary prevention, a gap exists between guidelines and practice in this cohort. It is also of concern that a low proportion of adults with a SCORE risk ≥5% were taking statins. A policy response that strengthens secondary prevention, and improves risk assessment and shared decision-making in the primary prevention of CVD is required.


Files in this item

Thumbnail
Name:
BMJOpen2015Murphy.pdf
Size:
1.211Mb
Format:
PDF
Description:
Main Article

This item appears in the following Collection(s)

Show simple item record